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Two previous investigations were performed to assess the activity of Gelsemium sempervirens (Gelsemium s.) in mice, using
emotional response models. These two series are pooled and analysed here. Gelsemium s. in various homeopathic centesimal
dilutions/dynamizations (4C, 5C, 7C, 9C, and 30C), a placebo (solvent vehicle), and the reference drugs diazepam (1mg/kg body
weight) or buspirone (5mg/kg body weight) were delivered intraperitoneally to groups of albino CD1 mice, and their eﬀects on
animal behaviour were assessed by the light-dark (LD) choice test and the open-ﬁeld (OF) exploration test. Up to 14 separate
replications were carried out in fully blind and randomised conditions. Pooled analysis demonstrated highly signiﬁcant eﬀects of
Gelsemium s. 5C, 7C, and 30C on the OF parameter “time spent in central area” and of Gelsemium s. 5C, 9C, and 30C on the
LD parameters “time spent in lit area” and “number of light-dark transitions,” without any sedative action or adverse eﬀects on
locomotion. This pooled data analysis conﬁrms and reinforces the evidence that Gelsemium s. regulates emotional responses and
behaviour of laboratory mice in a nonlinear fashion with dilution/dynamization.
1.Introduction
Gelsemium sempervirens (Loganiaceae) is a twining vine
containing the toxic strychnine-related alkaloids gelsemine,
gelsemine, and sempervirine [1]. At pharmacological doses,
Gelsemium s. has been reported to show sedative, analgesic,
and antiseizure properties [2–5]. In homeopathic Materia
Medica, Gelsemium s. is described as a remedy for a variety
of anxiety-like neurological and behavioural symptoms [6–
8], and there is a preliminary report [9] that homeopathic
dilutions/dynamizations of Gelsemium s. in mice counter the
eﬀects of the anxiogenic compound RO 15-3505 (inverse
agonist of benzodiazepines) in the labyrinth test. More
recently, Bousta et al. have reported that, in some but not
all experimental conditions, Gelsemium s. at the 5th, 9th,
and 15th centesimal homeopathic dilutions/dynamizations
(C) reduces stress-induced behavioural alterations of mice in
the staircase test and light-dark test [10]. However, all these
results represent reversals of the eﬀects of severe stress (con-
ditioned paradigm), and the ﬁndings vary widely depending
on the dose administered and the test performed. There is
therefore scope for further studies exploring the eﬀects of
Gelsemium s. in mouse models of emotional response, using
rigorous methods.
Experimental investigations carried out with highly
dilutedsolutionshavesuﬀeredfromproblemsofreplicability
between diﬀerent laboratories [11–13] and even within
the same laboratory using diﬀerent experimental protocols
[14]. To ﬁll this gap, we performed two separate series
of investigations [15, 16], using validated animal models,
namely, the light-dark choice test (LD) and the open-ﬁeld
explorationtest(OF),inordertoacquirevariousbehavioural
parameters widely used in neuropsychopharmacology for
drug screening [17]. In LD test, an increase in the amount
of time spent in the lit compartment is an indicator of
decreased anxiety, and the number of light-dark transitions
has been reported to be an indicator of activity exploration
over time. In OF, the total distance travelled in the arena
reﬂects general exploratory activity, which may be altered
by locomotor ability or motivational factors, and is reduced2 Evidence-Based Complementary and Alternative Medicine
in case of sedation, paralysis, or impairment of movements,
while the time spent and the distance travelled in centre
reﬂect anxiolytic-like activity.
In the ﬁrst paper [15], we describe the eﬀects of
Gelsemium s. 5C dilution/dynamization, followed by some
exploratory tests using the 7C and 30C. In essence, it
showed that, in the OF test, Gelsemium s. 5C, 7C, and 30C
signiﬁcantly increased the time spent and the distance trav-
elled in the central zone. Neither dilution/dynamization of
Gelsemium s. aﬀected the total distance travelled, indicating
that the behavioural eﬀect was not due to unspeciﬁc changes
in locomotor activity. In the LD test, Gelsemium s. 5C and
also 30C showed a positive eﬀect in the same direction as
diazepam but did not reach the statistical signiﬁcance. In the
lightofthesepartiallypositiveresults,wedecidedtocontinue
and intensify our study and undertook a new experimental
series with 6 replications of a similar protocol where a wider
range of Gelsemium s. dilutions/dynamizations (4C, 5C, 7C,
9C, 30C) was tested. Minor protocol diﬀerences concerned
the sequence of testing, the housing of animals, and the
supplier of mice (see Methods). A preliminary report of the
results of the second series appeared in a review [18], and
the complete study was published in Psychopharmacology
[16]. Gelsemium s. 5C, 7C, 9C, and 30C showed stimulatory
activity on the time spent and distance travelled in the
central zone of the OF, but this eﬀect did not go beyond
the threshold of statistical signiﬁcance (P = 0.060). On
the other hand, with the LD test parameters, in the second
series, the eﬀect of Gelsemium s. was much more evident and
signiﬁcant (P<0.01 in the global ANOVA for groups): the
medicament at the 5C, 9C, and 30C dilutions/dynamizations
increased the time spent in the light compartment (by
21.58%, 37.47%, and 21.85%, resp.) and the number of
transitions (by 24.66%, 40.01%, and 40.02%, resp.), with
high statistical signiﬁcance. These eﬀects were in the same
direction as those of diazepam and buspirone, tending to
conﬁrm an anxiolytic-like activity. In summary, these two
series of studies yielded qualitatively similar results, but
with notable quantitative variations. Others have recently
raised the issue of reproducibility of Gelsemium s. eﬀects
[19]. Therefore, in order to verify whether the eﬀects on the
considered behavioural variables are consistent, signiﬁcant,
and reproducible, we present here a complete summary of
these investigations, with a new analysis of pooled data.
2. Methods
2.1. Animals. All the experiments were performed at the
Faculty of Medicine, Verona University, Italy, with some
minor modiﬁcations between the two series of replications
(Table 1) .M a l em i c e4 - 5w e e k so l do ft h eC D 1s t r a i nw e r e
purchased from Harlan Laboratories (Udine, I) or Charles
River Laboratories (Lecco, I) and allowed to acclimate for
two weeks before testing, in a controlled animal facility
(temperature 22 ± 2◦C, humidity 55%±5 % ) .T h em i c ew e r e
randomly distributed, 4 per cage (size 349 × 156 × 132mm)
or 2 per cage (size: 250 × 140 × 120mm) in plastic cages,
and housed with food and water available ad libitum, except
Table 1: Features of the two series of experiments testing Gelse-
mium s. on mouse behaviour.
Series no. 1 Series no. 2
Mouse producer Harlan Charles River
Housing 4/cage 2/cage
Light/dark cycle Light during day
(h 7–19)
Light during day
(h 7–19)
Drug
administration
0.3mL/day for 8
days, i.p.
0.3mL/day for 8
days, i.p.
Test sequence
1st day:
light-dark
2nd day: open
ﬁeld
1st day: open
ﬁeld
2nd day:
light-dark
Test schedule
30min–320min
after last drug
administration
30min–90min
after last
injection
Number of
complete
experiments
Control
(solvent) 86
Diazepam 5 1
Buspirone n.t. 5
Gels 4C n.t. 6
Gels 5C 8 6
Gels 7C 3 6
Gels 9C n.t. 6
Gels 30C 2 6
for during the brief testing periods. Lights were on between
7A Ma n d7P M .
In each replication, groups of mice (n = minimum 8,
maximum 16) were randomly assigned to separate cages and
treated with diﬀerent solutions as indicated. The arrange-
ment of cages in the laboratory rack and the order in which
mice were injected and tested were evenly distributed for
all cages and experimental groups, to avoid cage eﬀects and
other possible biases linked to the timing of injections and
tests. Each animal was used only once in the same test to
avoid the confounding eﬀects of learning and habituation.
Each replication experiment lasted about 4 weeks, including
animal habituation, drug delivery, testing, and data collec-
tion and analysis.
2.2. Drugs and Treatments. The drugs were produced by
BoironLaboratoires,Lyon(F),startingfromacrudehydroal-
coholic extract of fresh underground portions of Gelsemium
s.,whichwasdiluted100timesin30%ethanol/distilledwater
to obtain the 1C dilution/dynamization. Subsequent serial
100 × dilutions followed by vigorous shaking (dynamiza-
tion) of up to 29C were then made in the same solvent,
using glass bottles. The content of gelsemine—the principal
alkaloid of Gelsemium s.—in the ﬁrst hydroalcoholic extract
was 0.021% (w/v), corresponding to a concentration of 6.5×
10
−4 moles/L. The control solution (vehicle) was the same
batchof30%ethanol/distilled watersolution usedtoprepare
the drug samples.Evidence-Based Complementary and Alternative Medicine 3
The solutions were stored in the dark at room tem-
perature in an aluminium envelope. Before being used
in each replication experiment, 0.4-mL samples of each
solution (including the control solution) were added to
39.6mL of distilled sterile and apyrogenic water in a
sterile 50-mL Falcon plastic tube, closed with a plastic cap,
and manually shaken with 20 strong vertical strokes to
obtain the ﬁnal drug samples and control vehicle used for
treatments,withﬁnalethanolconcentrationloweredto0.3%
(v/v). Diazepam (Valium, Roche, ﬁnal dose of 1mg/kg) or
buspirone (Sigma, ﬁnal dose of 5mg/kg) were diluted in
the ﬁnal vehicle solution (0.3% ethanol in distilled water).
Preliminaryexperiments,comparinga0.3%ethanolsolution
in distilled water (ﬁnal dose 0.03g/kg) with pure distilled
water, showed that this dose of diluted ethanol does not
aﬀect behaviour of mice in any of the test employed. In
ordertoblindtheoperatorswithrespecttothetestsolutions,
all the samples were then coded by an independent person
and the codes kept sealed inside an envelope until all the
tests and calculations were completed. The solutions were
distributedin15-mLsterileFalconplastictubes(4mL/tube),
wrapped in aluminium foil, and stored at +4◦C until
t h ed a yo fu s e .B e f o r eb e i n gu s e d ,e a c ht u b ew a sa g a i n
manually shaken with 20 strokes. All the procedures were
performed in sterile conditions and using sterile disposable
plasticware.
The drug and control solutions were administered in
the morning for 9 consecutive days (including on the last
two days, when the behavioural tests were carried out) by
intraperitoneal (i.p.) injection (0.3mL) using disposable 1-
mL (insulin) syringes. The diazepam-treated group received
thedrugsolutiononlyonthedaysoftesting,inconsideration
of the well-known development of tolerance to benzodi-
azepines [20] and their short half-life [21], and 0.3mL of
control solvent solution (0.3% ethanol/distilled water) for
the ﬁrst 7 days. The treatment and testing procedures were
independently approved by the Animal Ethics Committee of
theInterdepartmentalCentreforAnimalResearch(CIRSAL)
of Verona University and by the Italian Health Ministry.
Aside from the treatment injections and testing, the animals
were not subjected to pain or other forms of emotional or
physical stress.
2.3. Behavioural Tests. The OF behaviour test (Figure 1,
above) [22–24] involves placing an animal in an unfamiliar
environment consisting of a 50 × 50cm black-painted
wooden platform, with 25cm high surrounding walls, illu-
minated with white light (100 lux). The OF arena is virtually
divided into two parts, with a square central zone having an
area corresponding to 25% of the total area. The percentage
time spent in this central zone is considered indicative of
exploratory behaviour and may reﬂect a decrease in anxiety,
although this OF parameter is not sensitive to all anxiolytics
andmaynotmodelcertainfeaturesofanxietydisorders[24].
The LD exploration test (Figure 1,b o t t o m )[ 25–27]i s
based on the innate aversion of rodents to brightly lit areas,
and their spontaneous exploratory behaviour in response to
mild stressors such as novel environments and light. Mice
OF
LD
Walls
Virtual
central
area
A
B
B
A
Black
dark chamber
White, 
illuminated
area
Walls
∗
∗
Figure 1: Schematic representation of the arenas of the OF (above)
and LD (bottom) tests. The hypothetical bifurcation point of the
trajectorychoiceisindicatedbyanasterisk.(A)positiveeﬀectofthe
drug (less anxiety, less fear, more exploration attitude), (B) negative
eﬀect of the drug.
tend to prefer dark, enclosed spaces to large, well-lit areas,
and the amount of time spent in the dark zone is sensitive
to benzodiazepines and to the agonists of serotoninergic
receptors, in a manner that correlates well with clinical
eﬃcacy in humans [28]. The test apparatus consists of a
small, secure dark compartment (15 × 30cm), and a large,
aversive illuminated compartment (30 × 30cm). The two
compartments are separated by a partition with an opening
(4 × 4cm) through which the animal can pass from one
compartment to the other. The open arena is brightly illumi-
nated with 200 lux, and the mice are left to explore the space
for a 5min testing period. The score for the transition was
assigned, by a person not aware of the treatment assignment
of the groups, from the analysis of the video recordings,
when the animal came out of the dark chamber with all
4p a w s .
The animals were tested individually in 4 separate
devices, starting from 30min after last drug (or placebo)
administration. In the ﬁrst series of replications [15], the
treatments were delivered before all test procedures, and the
assays performed in the following order: LD on 8th day4 Evidence-Based Complementary and Alternative Medicine
of solution administration, OF on the following day (9th
day of solution administration). Since the best results were
obtained in the OF (see results), in the second series [16],
the assays were performed in the following order: OF on
8th day of solution administration, and LD on the following
day (9th day of solution administration). To match better
the timing of testing with that of drug administration, in
the second series of replications, the drugs were delivered
r o wb yr o w( 8c a g e so f2m i c ei ne a c hr o wo ft h eh o u s i n g
rack), followed by testing of the injected animals, so that
the test procedures were completed 80–90min after the
last treatment. Immediately before testing, the animals were
allowed to acclimate to the room inside their cages for three
minutes, after being brought there from their customary
housing area. The operators stayed outside the testing room
during the recording of the experimental sessions. In very
few cases, a mouse was lost because it jumped out of the test
arena during the test, and those cases were excluded from the
calculations. The test arenas were cleaned thoroughly with
waterandsoftdisposablepaperbetweentrialsandwithwater
and detergent between experiments.
2.4. Image Analysis System. A video-tracking camera and
software program (“Smart” VTS system from PanLab,
Barcelona, E) were used to record the sessions automatically.
Essentially, this system consists of a video-camera (GZ-
MG135, JVC, Japan) mounted on the ceiling 2.5m above
the centre of the experimental ﬁeld, a video interface, and
a computer. The camera views 4 test arenas, each of which
is in turn divided by the software into two zones, depending
on the test to be performed (LD or OF). All the sessions are
recorded and stored on DVDs. The acquired video signals
are converted by the image processor into binary images in
which the animal appears as a black spot against a white
background. The movements of the spot are recorded to
track the animals’ position, the amount of time spent in
diﬀerent zones, and the distance travelled.
2.5. Statistics. Up to 14 replications from two series of
studies were performed and analysed: 8 replications of the
same protocol in the ﬁrst series [15], and 6 replications
in the second series [16]. Analyses were performed using
the Stata12 software (http://www.stata.com) and the SPSS
17 software (http://www.spss.com). The eﬀect of the drugs
on each mouse was calculated as a percentage relative to
the mean values for the controls (vehicle-treated) in each
replication of the series, taken as zero eﬀect, according to the
formula:

Test value of each mouse
mean test value of control mice

−1

×100. (1)
This standardisation allowed the eﬀects observed in all
the experiments to be compared and statistically evaluated.
All data are represented as mean ± SEM (standard error
of the mean) values. The pooled data were normally
distributed. Nested ANOVA was used to ﬁnd any diﬀerences
in the studied parameters (time spent and distance travelled
in the centre of OF, total distance travelled in OF, time spent
in the lit area of LD box, number of dark-light transitions)
according to type of treatment and controlling for experi-
mental series, and replications (with replications nested in
experimental series). When global ANOVA was signiﬁcant
and there was no interaction between groups and series, the
data of the two series were pooled and speciﬁc comparisons
were assessed to determine diﬀerences between groups. Post
hoc t-tests were performed assuming equal variances with
least signiﬁcant diﬀerence corrections to adjust for multiple
comparisons (protected LSD), as suggested by a consensus
report [29] for basic research in high dilution/dynamization
pharmacology. Pearson correlation coeﬃcient (r)w a su s e d
to analyse the association between diﬀerent behavioural
variables in the control groups.
3. Results
3.1.OpenField. Theresultsofpoolingallthetestsperformed
with OF test is reported in Table 2. An interaction between
series and groups emerged only for the variable “distance in
centre” in OF that was therefore excluded from subsequent
analysis.
Inthevariable“timespentincentre,”adiﬀerencethatdid
not reach statistical signiﬁcance was noted in global ANOVA
for series. However, there was no interaction between series
and groups, indicating that the drug eﬀects were in the same
direction in all groups, albeit with quantitative diﬀerences.
Therewerehighlysigniﬁcantdiﬀerencesbetweengroups.
All Gelsemium s. samples except for 4C showed a stim-
ulatory activity as compared with control solvent, with a
statistically signiﬁcant diﬀerence for the 5C, 7C, and 30C
dilutions/dynamizations. Equally apparent is the lack of
eﬀect of the two standard drugs diazepam and buspirone
on these parameters, suggesting that this model system in
these experimental conditions was not suitable for detecting
a conventional anxiolytic eﬀect and hence that the eﬀect of
Gelsemium s. on mouse behaviour in the OF is qualitatively
diﬀerent from that of standard drugs (see also Discussion).
During the OF test, the total distance travelled by the
mice in the arena was also analysed (Table 2). Considering
the entire series of replications, no signiﬁcant diﬀerences
were found between various groups, although a small
inhibitory eﬀect was found in buspirone-treated versus
solvent-treated animals (−9.19%), suggesting a possible
sedative eﬀect instead of anxiolytic-like eﬀect. This phe-
nomenon was not present with diazepam and Gelsemium
s., suggesting that these drugs did not aﬀect the unspeciﬁc
locomotor activity of the mice and the observed diﬀerences
intimespentinthecentralzonewereduetogenuinechanges
of anxiety levels.
3.2. LD Test. As shown in Table 3, the time spent in the
open, illuminated (white) compartment of the LD test
arena increased in all the Gelsemium s.-treated groups
and in the groups treated with diazepam and buspirone.
Considering the whole of this large population of animals,
the eﬀects of Gelsemium s. C5, C9, and C30 proved
highly statistically signiﬁcant in post hoc analysis, withEvidence-Based Complementary and Alternative Medicine 5
Table 2: Cumulative results of open-ﬁeld test (14 replications in two experimental series§).
Tested
variable Tested samples Number of
mice
Eﬀect (% of control) ANOVA Post hoc
test Mean SEM For series For groups
Time in
centre
Control (solvent) 212 0.00 3.15
F = 4.44
P = 0.057
F = 4.72
P<0.0001
—
Diazepam (1mg/kg) 77 −1.20 6.96 0.867
Buspirone (5mg/kg) 40 8.48 8.02 0.362
Gels 4C 48 −4.35 6.43 0.614
Gels 5C 166 19.67 4.48 <0.001
Gels 7C 95 29.80 6.12 <0.0001
Gels 9C 48 13.82 7.05 0.110
Gels 30C 80 26.29 7.09 <0.001
Total
distance
Control (solvent) 213 0.00 1.52
F = 0.00
P = 0.951
F = 1.90
P = 0.066 —
Diazepam (1mg/kg) 79 3.56 3.52
Buspirone (5mg/kg) 40 −9.19 2.43
Gels 4C 48 2.45 3.03
Gels 5C 166 4.94 1.55
Gels 7C 94 3.45 2.04
Gels 9C 48 0.77 3.23
Gels 30C 79 4.96 2.54
§For series deﬁnition, see Table 1.
a peak at 9C dilution/dynamization. Similar results were
obtained by measuring the number of transitions between
compartments, with the diﬀerence, as compared with the
permanence time, that here only the eﬀects of 9C and 30C
dilutions/dynamizations provedto bestatisticallysigniﬁcant.
Moreover, in this test, parameter buspirone was less eﬀective
as positive control. Since this parameter is likewise linked
to physical motility, this may be due to the slight inhibitory
eﬀect of buspirone on unspeciﬁc locomotion already noted
in OF. In LD responses, there were no signiﬁcant diﬀerences
in the eﬀects in the two series.
3.3. Diﬀerences between Behavioural Parameters. The eﬀects
of Gelsemium s. displayed marked nonlinearity with dilu-
tion/dynamization and were diﬀerent in the OF and LD
assessments. In the OF, the 4C was inactive and showed
signiﬁcantly lower eﬀects than the 5C, 7C, and 30C. In the
LD, the activity of the 7C dilution/dynamization was very
low, while peak activation was noted using the 9C. In the
OF test, there was a signiﬁcant eﬀect of Gelsemium s. (peak
7C) but not of the conventional drugs, while, in the LD test,
both Gelsemium s. (peak 9C) and the conventional drugs
showed signiﬁcant eﬀects. These discrepancies strongly sug-
gestthatthetwotestparadigmsexplorediﬀerentbehavioural
symptoms which respond diﬀerently to conventional and
homeopathic drugs. This conclusion is supported by the
ﬁnding illustrated in Figure 2. Utilising all the data points for
untreated control mice, we observe a clear relation between
the two OF parameters (time spent and distance travelled in
the centre), indicating that both reﬂect a decision of whether
to stay in the peripheral area (thigmotaxis) or to explore the
central area. On the other hand, the time spent in the centre
of the OF does not correlate with the time spent in the lit
area of the LD, suggesting that these two parameters reﬂect
diﬀerent physiological features and behavioural parameters,
and this may be the reason for the diﬀering sensitivity to the
treatments.
4. Discussion
Natural remedies are frequently used by people suﬀering
from anxiety disorders, but evidence of their beneﬁts in
randomised controlled studies [30, 31]a n dl a b o r a t o r y
research [18] is limited. Due to the controversial nature of
homeopathic claims, it is important for any results in this
ﬁeldtobeconﬁrmedandconsolidatedthroughfurtherinves-
tigations and rigorous statistical evaluation. Two previous
investigations [15, 16] suggested that Gelsemium s. reduced
anxiety and fear and increased exploratory behaviour in
the laboratory mouse, without provoking any sedation side-
eﬀects. However, in the ﬁrst series, the major and most
signiﬁcant eﬀect was noted in OF parameters [15], while, in
thesecondone,theLDtestyieldedthebestresults[16].Since
reproducibility, the degree of accordance between the results
of experiments testing the same hypothesis, is a fundamental
requisite for acceptance of any evidence, we performed a new
analysis to evaluate statistically the diﬀerences between the
two series and the global signiﬁcance of the results.
In all parameters considered but one (distance travelled
in centre in OF), there were no signiﬁcant diﬀerences
between the two experimental series nor interaction between
series and experimental groups. This indicates that the
trends of the drug eﬀects were qualitatively in the same
direction, despite a noteworthy quantitative variability. The
pooled data analysis conﬁrms and reinforces the evidence
that statistically high signiﬁcant Gelsemium s. eﬀects can be6 Evidence-Based Complementary and Alternative Medicine
Table 3: Cumulative results of light-dark test (14 replications in two experimental series§).
Tested
variable Tested samples Number of
mice
Eﬀect (% of control) ANOVA Post hoc
test Mean SEM For series For groups
Time in lit
area
Control (solvent) 215 0.00 3.95
F = 6.31
P = 0.24
F = 3.60
P<0.001
—
Diazepam (1mg/kg) 77 34.85 8.93 <0.0001
Buspirone (5mg/kg) 40 25.81 6.82 0.015
Gels 4C 48 18.15 8.47 0.066
Gels 5C 165 14.94 5.56 0.019
Gels 7C 95 6.71 5.73 0.377
Gels 9C 48 37.47 7.04 <0.001
Gels 30C 79 16.15 6.27 0.047
Light/dark
transitions
Control (solvent) 213 0.00 4.39
F = 7.69
P = 0.09
F = 9.42
P<0.0001
—
Diazepam (1mg/kg) 78 86.78 15.70 <0.0001
Buspirone (5mg/kg) 40 11.88 6.60 0.386
Gels 4C 48 21.78 11.43 0.086
Gels 5C 165 16.09 6.87 0.051
Gels 7C 95 7.22 5.60 0.461
Gels 9C 48 40.01 9.09 0.002
Gels 30C 79 33.12 7.43 0.002
§For series deﬁnition, see Table 1.
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Figure 2: Correlations (Pearson’s r)b e t w e e nd i ﬀerent behavioural variables explored by the OF and LD tests. The data points for mice from
the control groups of all replications were utilised.
detected in the laboratory mouse using both the OF and
LD paradigms, even with the high dilutions/dynamizations
employedinthehomeopathicpharmacopoeia(9Cand30C).
This laboratory evidence, based on blinded protocols and
using groups of large sample size, strongly supports the
conclusion that homeopathic medicaments are not mere
placebos and are endowed with speciﬁc pharmacological
activity.
The ability of extremely diluted drugs to change these
emotional responses of mice can be ascribed to the high
sensitivity of the tests involved, which are designed to put
the animal in a situation of uncertainty (“bifurcation point,”
indicated by an asterisk in Figure 1), where an extremely
slight inﬂuence can determine the choice of which direction
to move in (A or B in ﬁgure). The sensitivity of these tests
to minimal factors is also, conceivably, one reason for the
high variability of responses in the two series of experiments,
observed in both vehicle-treated and drug-treated animals.
It has been noted that the extent to which an anxiolytic
compound facilitates exploratory activity depends on its
baseline level in the control group [25]. Bousta et al. [10]
report some anxiolytic-like eﬀects of G. sempervirens in miceEvidence-Based Complementary and Alternative Medicine 7
stressed by repeated electric shocks, but no such eﬀects
in normal unstressed mice. Diﬀerences between the nature
and severity of external stressors, or between experimental
setups, environment, handling and testing, and individual
biological responses to drugs, might account for the high
variability of results reported under diﬀerent experimental
conditions [24, 32, 33]. Variable behavioural baseline levels
have been reported by others [17, 34], and it has been
found that two groups having low and high “trait” anxiety
and diﬀerent neuroendocrine responses to stress can be
selected from the same mouse population [35], indicating
thatexpressionoftraitanxietydisplaysahighinterindividual
variability in inbred mice.
In the OF model, Gelsemium s.-treated mice were
unaﬀected in their general movement and locomotion in
the ﬁeld but showed a higher tendency to enter the central
zone, instead of running along the walls or staying in the
corners. This behaviour is thought to reﬂect changes in
the emotional state of the mouse, even though in our
experimental conditions, the OF parameters do not measure
“anxiety” but rather exploratory propensity, thigmotaxis,
and neophobia. This conclusion is based on the fact that
neither buspirone nor diazepam altered those parameters.
Thediﬀerences between the eﬀectsof Gelsemium s. and those
oftheconventionalanxiolyticdrugsdiazepamandbuspirone
suggest that the former has a broader action on animal
behaviour, possibly including the stimulation of exploratory
behaviour in the OF. The LD, on the other hand, proved to
be a very valid test for anxiety, given that it always showed
some eﬀect with the two conventional anxiolytics, as well as
with Gelsemium s.
Anxiety, neophobia, fear, and thigmotaxis are rather
complex phenomena. There are two types of anxiety, “state”
anxiety (excess anxiety experienced by a subject at a par-
ticular time in presence of a stimulus) and “trait” anxiety
(does not vary from moment to moment) [36]. It has been
suggested that the light-dark test and elevated plus-maze
device are the most appropriate models for assessing state
anxiety, while the free-exploratory paradigm can be used
for “trait anxiety” [33, 37]. It has also been reported that
anxiolytic treatments do not by themselves increase explo-
ration in the central zone of the OF, but they do decrease
the stress-induced inhibition of exploratory behaviour [17].
Benzodiazepines have been found to be inactive in some
models or even to produce paradoxical anxiogenic eﬀects
[38]. That OF is less sensitive to benzodiazepines, and
buspirone as compared with other behavioural tests, (e.g.,
elevated plus-maze) has been shown also by others [39],
and a decrease of locomotion caused by buspirone at low
(1mg/kg) and high (10mg/kg) doses has been observed in
rats [40]. Further studies with additional tests of anxiety are
needed to conﬁrm this intriguing relationship.
These ﬁndings strongly suggest that the LD and OF
tests explore diﬀerent emotional responses, with diﬀerent
sensitivitiestodrugsandneurologicalmechanisms.Ourdata
showing lack of correlation between responses with two test
used (Figure 2) seem in agreement with this conclusion.
In this connection, it is also worth noting that the peak
of Gelsemium s. activity in the LD test was observed with
the 9C dilution dynamization, while, in the OF, it occurred
with the 7C. This may suggest that the diﬀerent behavioural
“symptoms” exploited by these two test paradigms are
sensitive to diﬀerent dilutions/dynamizations of the remedy.
A possible action mechanism of Gelsemium s. at neu-
rological level has been indicated by others, showing that,
in rat brain slices, very low doses [41] and high dilutions/
dynamizations (5C, 9C) of this compound [42]e n h a n c e
the production of the neurosteroid allopregnanolone (5a,3a-
tetrahydroprogesterone), a stimulator of GABAa receptors
and of inhibitory signalling in the central nervous system.
These authors [41] showed that this activity was stimulated
byglycineandblockedbystrychnine,wellknownasaglycine
receptor (Gly-R) antagonist, suggesting that gelsemium
eﬀects are antagonistic to those of strychnine and mediated
by Gly-R receptors.
Gelsemium s. is frequently used in homeopathy to treat
patients exhibiting neurological anxiety-like symptoms such
as “general prostration, trembling, tired feeling, mental
apathy, muscular weakness, complete relaxation and pros-
tration, lack of muscular co-ordination, general depression,
emotional excitement, bad eﬀects from fright, fear, exciting
news” according to the Materia Medica [6–8]. The fact that
the traditional indications for the remedy are consistent with
signiﬁcant laboratory ﬁndings using rigorous experimental
models helps bridge a gap between two medical disciplines
generally considered to be at variance with each other, but
which should instead be regarded as complementary and
compatible. Of course, further scientiﬁc evidence of possible
clinical beneﬁts of homeopathy in humans is needed.
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